<SEC-DOCUMENT>0001213900-15-009144.txt : 20151127
<SEC-HEADER>0001213900-15-009144.hdr.sgml : 20151126
<ACCEPTANCE-DATETIME>20151127163329
ACCESSION NUMBER:		0001213900-15-009144
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20151120
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151127
DATE AS OF CHANGE:		20151127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		151258234

	BUSINESS ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k112015_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B><BR>
<B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">Date of Report (Date of earliest event reported): November
20, 2015</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt"><B>000-52446</B></TD>
    <TD STYLE="width: 2%; padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt"><B>74-2963609</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">(State or other jurisdiction<BR>
of incorporation)</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">(Commission File Number)</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">(IRS Employer<BR>
Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt"><B>757 Third Avenue, 21st Floor</B><BR>
<B>New York, NY</B></TD>
    <TD STYLE="width: 2%; padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt"><B>10017</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">(Address of principal executive offices)</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0pt">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">Registrant&rsquo;s telephone number, including area
code: <B>(732) 243-9495</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-family: Times New Roman,serif; text-align: center"><B>N/A</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-family: Times New Roman,serif; text-align: center">(Former name or former address, if changed since last report)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: MS Mincho">&#9744;</FONT>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: MS Mincho">&#9744;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: MS Mincho">&#9744;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: MS Mincho">&#9744;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
issued a press release on November 25, 2015 regarding a letter that was sent to shareholders outlining recent and expected milestones.
A copy of the Company&rsquo;s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
into this Item&nbsp;8.01 by reference. On November, 25, 2015, the Company also issued a press release regarding the filing of an
Application for Orphan Drug Designation with the U.S. Food and Drug Administration for Iomab-B, a radioimmunotherapeutic that conditions
refractory and relapsed Acute Myeloid Leukemia patients for a Hematopoietic Stem Cell Transplant, commonly referred to as a Bone
Marrow Transplant. A copy of the Company&rsquo;s press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and
is incorporated into this Item&nbsp;8.01 by reference.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt; text-indent: 0pt"><B>Item 5.03.&#9;Amendments to Articles of Incorporation
or Bylaws; Change in Fiscal Year.</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 20, 2015, pursuant to
Section 10.1 of the Amended and Restated Bylaws (as amended, the &ldquo;Bylaws&rdquo;) of the Company, the board of directors
of the Company adopted the Second Amendment to the Amended and Restated Bylaws of the Company (the &ldquo;Second A&amp;R
Bylaws&rdquo;), effective immediately upon adoption. The Second A&amp;R Bylaws reduce the quorum required for the
Company&rsquo;s annual meeting of stockholders from a majority to thirty-four percent (34%) of the voting power of the shares
of the Company. A copy of the Second A&amp;R Bylaws is attached as Exhibit 3.2 to this Current Report on Form 8-K and is
incorporated into this Item&nbsp;5.03 by reference.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0"><I>(d) Exhibits.</I></P>

<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release, dated November 25, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.2</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release, dated November 25, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>3.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>Second Amendment to Amended and Restated Bylaws, effective as of November 20, 2015</TD></TR>
</TABLE>
<P STYLE="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman,serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">Dated: November 27, 2015</TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt"><B>ACTINIUM PHARMACEUTICALS, INC. </B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt; width: 5%">By: </TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt; width: 35%; border-bottom: Black 1.5pt solid"><I>/s/ Kaushik J. Dave</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">Name:</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">Kaushik J. Dave</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">Title:</TD>
    <TD STYLE="padding: 0pt; font-family: Times New Roman,serif; text-indent: 0pt">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; text-align: center; margin-bottom: 0">3</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>f8k112015ex3ii_actinium.htm
<DESCRIPTION>SECOND AMENDMENT TO THE AMENDED AND RESTATED BYLAWS, AS AMENDED
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECOND AMENDMENT TO THE AMENDED AND RESTATED
BYLAWS, AS AMENDED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>APPROVED BY THE BOARD OF DIRECTORS OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EFFECTIVE AS OF NOVEMBER 20, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 2.4 of the Amended
and Restated Bylaws, as amended (the &ldquo;<U>Bylaws</U>&rdquo;) of Actinium Pharmaceuticals, Inc. (the &ldquo;<U>Corporation</U>&rdquo;)
is hereby amended to replace Section 2.4 thereof, and the following Section 2.4 be, and hereby is, is authorized, approved and
adopted in all respects and, as amended, said Section 2.4 shall be deemed to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify"><B>&ldquo;Section 2.4&nbsp;&nbsp;Quorum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">Unless otherwise required by law at each
meeting of the stockholders, thirty-four percent (34%) in voting power of the shares of the Corporation entitled to vote at the
meeting, present in person or represented by proxy, shall constitute a quorum for all purposes, unless or except to the extent
that the presence of a larger number may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">If a quorum shall fail to attend any
meeting, the chairman of the meeting or the holders of a majority of the shares of the stock entitled to vote who are present,
in person or by proxy, may adjourn the meeting to another place, date or time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">If a quorum shall fail to attend any
meeting, the presiding officer may adjourn the meeting to another place, date, or time.&nbsp; When a meeting is adjourned to another
place, date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are announced
at the meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than thirty
(30) days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting,
written notice of the place, date, and time of the adjourned meeting shall be given in conformity herewith.&nbsp;&nbsp;At any
adjourned meeting, any business may be transacted that could have been transacted at the original meeting.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>f8k112015ex99i_actinium.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: 14pt Times New Roman, Times, Serif; background-color: white"><B>Actinium
Issues Letter to Shareholders&nbsp;Outlining Recent and Expected Milestones</B></FONT><B><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
</FONT></B><BR>
<BR>
<FONT STYLE="font: 12pt Times New Roman, Times, Serif; background-color: white"><I>Iomab-B IND Filing, Clinical Progress and Competitive
Position of Actimab-A,</I></FONT><BR>
<FONT STYLE="font: 12pt Times New Roman, Times, Serif; background-color: white"><I>Create Solid Outlook for Drug Candidates Positioning
Company for a Strong 2016</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>NEW
YORK, NY &ndash; November 25, 2015 -&nbsp;</B>Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (&quot;Actinium&quot; or &quot;the
Company&quot;), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers, announced today that it has issued a letter to its shareholders&nbsp;outlining the Company&rsquo;s recent and expected
milestones. Highlights include: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B><U>Key
Achievements in 2015</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; text-align: justify; width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>Submitted
    the Iomab-B IND filing in November 2015</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>Completed
    the majority of the Phase 1 clinical trial for Actimab-A which will enable the Phase 2 trial to start in 2016 </B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>Actimab-A&rsquo;s
    positive results imply leadership position in the renewed race for CD-33 targeting drugs in AML</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>Started
    work on an exciting new indication for one of the drug candidates, with proof of concept studies expected in 2016</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>Successfully
    labeled an antibody with Actinium-225, creating an exciting new pipeline candidate with broad hematology applications</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0pt; font-family: Calibri,sans-serif; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>Strengthened
    development team with key senior level hires ahead of the upcoming Phase 3 clinical trial for Iomab-B and Phase 2 trial for
    Actimab-A in 2016</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&quot;In
2015, the Company achieved several significant milestones for Actimab-A and Iomab-B.&nbsp; With a strong balance sheet and focused
strategic plan, we believe we have positioned ourselves&nbsp;to advance both projects forward and to achieve milestones in 2016.
We look forward to 2016 and beyond with confidence,&rdquo; said Kaushik J. Dave, Ph.D., MBA, Chief Executive Officer of Actinium
Pharmaceuticals. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">To
read the Letter to Shareholders in full, please visit:&nbsp;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><U>http://ir.actiniumpharma.com/shareholder-letters</U></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>About
Actinium Pharmaceuticals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary
delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals
in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be
used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.
The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients
over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is
continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Forward-Looking
Statement for Actinium Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
news release contains &ldquo;forward-looking statements&rdquo; as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results
to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product
development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Investor
and Media Relations: &#9;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert
Haag&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Managing
Partner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IRTH
Communications&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>atnm@irthcommunications.com
&#9;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1-866-976-4784</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve
O'Loughlin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Senior
Director, Finance and Corporate Development</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium
Pharmaceuticals, Inc.</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>soloughlin@actiniumpharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0pt 0pt 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>f8k112015ex99ii_actinium.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B>Actinium
Files Orphan Drug Application for Use of Iomab-B in Treating</B></FONT><BR>
<FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B>Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><I>Orphan
Drug Designation Could Provide Faster Regulatory Review and Financial Incentives</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NEW
YORK, NY &ndash; November 23, 2015</B> Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (&quot;Actinium&quot; or &quot;the Company&quot;),
is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.
Actinium announced today that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration
(FDA) for Iomab-B, a radioimmunotherapeutic that conditions refractory and relapsed Acute Myeloid Leukemia (AML) patients for
a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). The Company has recently
submitted an Investigational New Drug (IND) application for Iomab-B with the FDA and is preparing for a pivotal, Phase 3 trial.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Kaushik
J. Dave, Ph.D., MBA, CEO of Actinium stated, &ldquo;We are pleased to have filed an Application for Orphan Drug Designation for
Iomab-B. We are confident that Iomab-B meets the criteria for Orphan Drug Designation and are eager to begin the Phase 3, pivotal
trial for Iomab-B. Acute Myeloid Leukemia is the most common acute leukemia affecting adults and accounts for the largest number
of annual deaths due to leukemia. Refractory and relapsed AML patients, particularly elderly patients, have very few, if any,
treatment options other than a Bone Marrow Transplant. Unfortunately, many of these patients cannot tolerate the intensive chemotherapy
given prior to BMT. We believe that Iomab-B will allow a greater number of AML patients to receive a BMT and could be a paradigm
shift in the way AML patients are treated.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium&rsquo;s
Actimab-A, which is intended to treat newly diagnosed AML patients over the age of 60, received Orphan Drug Designation on December
1, 2014. Results from the Phase 1 portion of Actimab-A&rsquo;s Phase1/2 trial will be presented at the 57<SUP>th</SUP> American
Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida on December 4 &ndash; 8, 2015. Actimab-A data, including
patients from the fourth and final cohort, will be presented in a poster session on December 7, 2015 at 6 pm EST.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>About
Orphan Drug Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
FDA, through its Office of Orphan Products Development (OOPD), grants orphan status to drugs and biologic products that are intended
for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people
in the U.S. Orphan drug designation provides a drug developer with certain benefits and incentives, including a period of marketing
exclusivity if regulatory approval is ultimately received for the designated indication; potential tax credits on U.S. clinical
trials; eligibility for orphan drug grants; and waiver of certain administrative fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>About
Iomab-B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Iomab-B
is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed
by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells.
This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation
in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic
leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM).
When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while
avoiding effects of radiation on most healthy tissues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>About
Actinium Pharmaceuticals </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary
delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals
in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be
used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.
The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients
over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is
continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
news release contains &quot;forward-looking statements&quot; as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results
to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product
development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve
O'Loughlin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Senior
Director, Finance and Corporate Development</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium
Pharmaceuticals, Inc.</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>soloughlin@actiniumpharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>



<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "0 80# 2(  A$! Q$!_\0
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MTXB7K;S-YD1'IM/3\,4 ?8U%>;> /B]IOBZ2/3=0C73]7;A8RV8YS_L$]_\
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MA:OV=+C=^C UYKXP^"6N>'H)+W2I?[6LD!9U1-LR#UV_Q?AS[5]"?\)-H/\
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M_"-ZW_T!-0_\!7_PH_X1O6_^@)J'_@*_^%=C_P +C\1?\^NG?]^W_P#BJ/\
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M-]=PQ!);DKM,A'?_ .OWK1HHKF- HHHI@%%%% !1110 4444 %%%% !1110
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
